A Phase 3 study evaluating nivolumab in treating patients with localized kidney cancer undergoing nephrectomy reached primary completion on 2023-05-24. The trial's primary analysis showed no statistically significant difference in outcomes between the nivolumab arm and the control arm, with a Cox Proportional Hazard p-value of 0.34.
Background
Nivolumab is an immunotherapy designed to stimulate the immune system to target cancer cells. This Phase 3 trial investigated its use as an adjuvant therapy following nephrectomy for localized kidney cancer, specifically in patients with conditions such as Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, and Unclassified Renal Cell Carcinoma.
Trial design
The Phase 3 study (NCT03055013) enrolled 819 participants with localized kidney cancer. The trial compared the approach of nephrectomy combined with nivolumab (Arm A) against nephrectomy followed by standard post-operative follow-up and monitoring (Arm B). The primary objective was to assess whether the addition of nivolumab could prevent cancer recurrence after surgery.
Key results
The trial reported the following key measurements and analyses:
- The Recurrence-free Survival (RFS) Rate at 5 Years was 0.63 proportion of participants for Arm A (Nephrectomy + Nivolumab) and 0.605 proportion of participants for Arm B (Nephrectomy Only).
- The Recurrence-free Survival (RFS) Rate at 3 Years Among Patients With Clear Cell Histology was 0.663 proportion of participants for Arm A (Nephrectomy + Nivolumab) and 0.675 proportion of participants for Arm B (Nephrectomy Only).
- The Overall Survival Rate at 5 Years was 0.73 proportion of participants for Arm A (Nephrectomy + Nivolumab) and 0.811 proportion of participants for Arm B (Nephrectomy Only).
The trial's primary analysis, using the Log Rank method, yielded a Cox Proportional Hazard of 0.95 with a 95.0% Confidence Interval ranging from 0.74 to 1.22, and a p-value of 0.34. This indicates no statistically significant difference between the two treatment arms.
What this means
The results of this Phase 3 trial suggest that adding nivolumab to nephrectomy for localized kidney cancer did not demonstrate a statistically significant improvement in recurrence-free survival or overall survival compared to nephrectomy alone. The primary analysis, with a p-value of 0.34, indicates that any observed numerical differences in outcomes, such as the 5-year recurrence-free survival rate of 0.63 for the nivolumab arm versus 0.605 for the control arm, or the 5-year overall survival rate of 0.73 for the nivolumab arm versus 0.811 for the control arm, are likely due to chance rather than a treatment effect. Clinicians should consider these findings when evaluating adjuvant treatment strategies for patients with localized kidney cancer post-nephrectomy.
Source
The information for this article was sourced from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT03055013, titled "Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy", was updated with primary completion information on 2023-05-24 on clinicaltrials.gov.